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1.  The first line of defense is filled with a variety of pattern recognition 
receptors
Pattern recognition receptors (PRRs), which are germ line-encoded recep-
tors, probably provided the host with the best possible innate property to identify 
“nonself” invaders from both exogenous and endogenous sources. PRRs can 
discriminate self-microorganisms and molecules from nonself ones through recog-
nizing conserved parts of microorganisms—which are known as microorganism-
associated molecular patterns (MAMPs). If it is nonself, then they will direct the 
induction of inflammatory responses. In addition, PRRs allow the innate immunity 
to identify endogenous danger signals—which are released by stressed, damaged, 
or dying cells and known as damage-associated molecular patterns (DAMPs)—and 
thereby help in initiation of sterile inflammation. In this manner, PRRs participate 
in the clearance of invading pathogens by regulating infectious inflammation and 
contribute to tissue repair and regeneration in addition to elimination of autoimmu-
nity and tumorigenesis by regulating sterile inflammatory processes.
They display three types of localization. Toll-like receptors (TLRs) are a kind of 
PRRs located in the membrane along with C-type lectin receptors. Also, nucleotide 
oligomerization domain (NOD)-like receptors (NLR) and retinoic acid-inducible 
gene I (RIG-I)-like receptors (RLR) are found in the nucleus and contribute to 
recognition of intracellular microorganisms. Finally, there are some proteins that 
their synthesis occurs in the cells and can be used as receptors by various micro-
organisms. TLRs—which are the subject of this book—were the first discovered 
family of PRRs.
2. Toll-like receptors
They exist in mammals and insects and mediate actions essential to achieve 
control over immune homeostasis. The major cells expressing TLRs are antigen-
presenting cells (APCs). Activation of TLRs in APCs can affect maturation of 
these cells and T helper 1 (Th1) cell differentiation for processing more specific 
immune mechanisms [1]. However, different cell types of the body have the 
capacity to induce the expression of TLRs, allowing them to carry TLR-mediated 
signaling pathways and production of inflammatory mediators and type I inter-
ferons (IFN). When handling a number of immune and inflammatory pathways, 
TLRs are able to have a role in the induction of innate immune responses and 
to link the innate immunity with the acquired immunity. Interfering with TLR 
function leads inevitably to immunological anomalies seen in common conditions 
ranging from immunodeficiency and infection to allergy, autoimmunity, cancer 
and more generally to diseases of many organ systems including the central 
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nervous system, lung, cardiovascular system, kidney, skin, and gastrointestinal 
system which are rooted in chronic inflammation. This has been fuel for advances 
in prophylactic and therapeutic applications of TLRs, especially in the last two 
decades.
2.1 Cells expressing TLRs
TLRs are found on the different cells of both the innate and adaptive immu-
nity. Notably, they are expressed by nonimmune cells in the body. Normal non-
transformed cells, such as endothelial cells, epithelial cells, fibroblasts, glial cells, 
neurons, and neural progenitor cells, as well as transformed cells of the body, i.e., 
cancer cells, may mediate the expression of TLRs. In humans, intestinal epithelial 
cells (IECs) are the main nonimmune source of TLRs. It is not aimless—there is 
evidence that the recognition of commensal bacteria by TLRs is required for the 
regulation of intestinal homeostasis [2].
2.2 Structure of TLRs
To date, 13 TLRs have been described in mammals, 10 of which are present in 
humans (TLR1–10). Each TLR consists of three domains: intracellular, transmem-
brane, and extracellular. The intracellular or cytoplasmic domain is conserved 
between TLRs and interleukin-1 family of receptors (IL-1R). It is, thus, referred to 
as the Toll-IL-1R (TIR) domain. The extracellular domain includes tandem leucine-
rich repeats (LRRs), which with their curved surface appear to determine which 
ligand(s) a TLR can bind. The transmembrane location of TLRs makes them very 
suitable to transmit signals from the extracellular matrix to the cytoplasm (signal 
transduction).
2.3 Cellular distribution of TLRs
TLRs are located either within the cell membrane or in the intracellular com-
partments including the endoplasmic reticulum, endosomes, lysosomes, and 
endolysosomes:
Cell-membrane TLRs: TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10
Intracellular TLRs: TLR3, TLR7, TLR8, and TLR9
Like other receptors, TLRs act in relation to their cellular distribution. Cell-
membrane TLRs are eligible for identification of membrane components of micro-
organisms, e.g., lipids, proteins, and lipoproteins, while intracellular TLRs are for 
identification of nuclear components of microorganisms, i.e., nucleic acids.
2.4 Ligands of TLRs
In general, MAMPs are divided into three: glycans, proteins, and nucleic acids. 
Particularly, ligands that participate in host-pathogen interactions vary based on 
the pathogen identity and include:
 Bacteria: lipoteichoic acid, peptidoglycan, lipoprotein/lipopeptides, deoxyribo-
nucleic acid (DNA), flagellin, and lipopolysaccharide
Viruses: coat proteins and nucleic acids
Parasites: glycosylphosphatidylinositol (GPI) protein-membrane anchors
Yeast: zymosan
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Cellular 
distribution 
[3]
Expressing cell type Exogenous ligands [4]
Innate immune cells Adaptive 
immune cells
IECs Cancer 
cells
Bacteria
Ligand (origin)
Viruses
Ligand (origin)
Fungi
Ligand (origin)
Protozoa
Ligand (origin)
TLR1 Cell surface Monocyte/macrophage
Neutrophils
MDCs
PDCs
B cells × × Lipopeptides
Soluble factors (N. 
meningitidis)
× × ×
TLR2 Cell surface Monocyte/macrophage
Neutrophils
MDCs
Mast cells
× × Gastric 
cancer
Colorectal 
cancer
Ovarian 
cancer
Cervical 
cancer
Lung 
cancer
Melanoma
Brain 
cancer
Breast 
cancer
Liver 
cancer
Laryngeal 
cancer
Pancreatic 
cancer
Lipoprotein/lipopeptides 
(GPB, mycoplasma, 
mycobacteria, 
Spirochetes)
Peptidoglycan (GPB)
Lipoteichoic acid (GPB)
PSM (S. epidermidis)
HKB (L. monocytogenes)
Porins (Neisseria)
Soluble factors (N. 
meningitidis)
Atypical LPS (L. 
interrogans, P. gingivalis)
OmpA (K. pneumoniae)
Glycolipids (T. 
maltophilum)
LAM (mycobacteria)
HA (MV)
SVP (HSV, 
CMV)
Zymosan 
(Saccharomyces)
PLM (C. 
albicans)
GIPLs (T. cruzi)
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Cellular 
distribution 
[3]
Expressing cell type Exogenous ligands [4]
Innate immune cells Adaptive 
immune cells
IECs Cancer 
cells
Bacteria
Ligand (origin)
Viruses
Ligand (origin)
Fungi
Ligand (origin)
Protozoa
Ligand (origin)
TLR3 Intracellular 
endosomal 
compartment
MDCs B cells
T cells
× Colorectal 
cancer
Ovarian 
cancer
Cervical 
cancer
Lung 
cancer
Melanoma
Breast 
cancer
Liver 
cancer
Laryngeal 
cancer
× dsRNA × ×
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Cellular 
distribution 
[3]
Expressing cell type Exogenous ligands [4]
Innate immune cells Adaptive 
immune cells
IECs Cancer 
cells
Bacteria
Ligand (origin)
Viruses
Ligand (origin)
Fungi
Ligand (origin)
Protozoa
Ligand (origin)
TLR4 Cell surface Monocyte/macrophage
Neutrophils
MDCs
Mast cells
B cells  Gastric 
cancer
Colorectal 
cancer
Ovarian 
cancer
Cervical 
cancer
Lung 
cancer
Prostate 
cancer
Melanoma
Brain 
cancer
Breast 
cancer
Liver 
cancer
Laryngeal 
cancer
LPS (GNB)
Hsp60 (C. pneumonia)
Envelope 
proteins (RSV 
and MMTV)
Fusion protein 
(RSV)
× GIPLs (T. cruzi)
TLR5 Cell surface Monocyte/macrophage
Neutrophils
MDCs
×  Breast 
cancer
Gastric 
cancer
Colorectal 
cancer
Ovarian 
cancer
Cervical 
cancer
Flagellin (flagellated 
bacteria)
× × ×
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Cellular 
distribution 
[3]
Expressing cell type Exogenous ligands [4]
Innate immune cells Adaptive 
immune cells
IECs Cancer 
cells
Bacteria
Ligand (origin)
Viruses
Ligand (origin)
Fungi
Ligand (origin)
Protozoa
Ligand (origin)
TLR6 Cell surface Monocyte/macrophage
Neutrophils Mast cells
MDCs
PDCs
B cells × Liver 
cancer
Diacyl lipopeptides 
(mycoplasma)
Lipoteichoic acid (GPB)
PSM (S. epidermidis)
HLSF (group B 
streptococcus)
Zymosan 
(Saccharomyces)
TLR7 Intracellular 
endosomal 
compartment
Monocyte/macrophage
Neutrophils
DCs
B cells × × × ssRNA × ×
TLR8 Intracellular 
endosomal 
compartment
Monocyte/macrophage
Neutrophils
MDCs
Mast cells
×  × × ssRNA × ×
TLR9 Intracellular 
endosomal 
compartment
Monocyte/macrophage
Neutrophils
PDCs
B cells
T cells
× Gastric 
cancer
Colorectal 
cancer
Cervical 
cancer
Lung 
cancer
Prostate 
cancer
Breast 
cancer
Liver 
cancer
Unmethylated CpG DNA Unmethylated 
CpG DNA
× Hemozoin 
(Plasmodium)
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Cellular 
distribution 
[3]
Expressing cell type Exogenous ligands [4]
Innate immune cells Adaptive 
immune cells
IECs Cancer 
cells
Bacteria
Ligand (origin)
Viruses
Ligand (origin)
Fungi
Ligand (origin)
Protozoa
Ligand (origin)
TLR10 Cell surface Monocyte/macrophage B cells  × Triacylated lipopeptides × × ×
GPB, gram-positive bacteria; IEC, intestinal epithelial cells; LPS, lipopolysaccharides; OmpA, outer membrane protein A; HSV, herpes simplex virus; CMV, cytomegalovirus; GIPLs, 
glycoinositolphospholipids; dsRNA, double-stranded RNA; GNB, gram-negative bacteria; DCs, dendritic cells; MMTV, mouse mammary tumor virus; RSV, respiratory syncytial virus; ssRNA, single-
stranded RNA; MDS, myeloid dendritic cells; N. meningitides, Neisseria meningitides; PDCs, plasmacytoid dendritic cells; S. epidermidis, Staphylococcus epidermidis; PSM, phenol-soluble modulin; HKB, 
heat-killed bacteria; L. monocytogenes, Listeria monocytogenes; L. interrogans, Leptospira interrogans; P. gingivalis, Porphyromonas gingivalis; K. pneumoniae, Klebsiella pneumoniae; T. maltophilum, 
Treponema maltophilum; LAM, lipoarabinomannan; PLM, phospholipomannan; T. cruzi, Trypanosoma cruzi; C. albicans, Candida albicans; HA, hemagglutinin; MV, measles virus; SVP, structural viral 
proteins; C. pneumonia, Chlamydia pneumonia; HLSF, heat-labile soluble factor.
Table 1. 
Toll-like receptors: cellular distribution, expressing cell types, and exogenous ligands.
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TLRs have been reported to bind endogenous and exogenous ligands. There is a 
wide range of microorganisms including bacteria, viruses, protozoa and helminth 
parasites, and fungi that TLRs can defend against. Table 1 provides an overview 
of ligands and associated pathogens that interact with TLRs. However, below are 
representative examples for MAMPs that can be recognized by TLRs:
TLR1: lipoproteins
TLR2: lipoteichoic acid, peptidoglycan, lipoproteins, and zymosan
TLR3: viral dsRNA
TLR4: lipopolysaccharide, viral envelope protein, and viral fusion protein
TLR5: flagellin
TLR6: lipoteichoic acid, lipoproteins, and zymosan
 TLR7 and TLR8: viral ssRNA, synthetic antiviral compounds 
(imidazoquinolines)
TLR9: bacterial and viral DNA
TLR10: triacylated lipopeptides
Endogenous ligands that can be recognized by TLRs are numerous but 
mainly include extracellular matrix components, high-mobility group box 1, 
heat shock proteins (HSP), tenascin-C, cardiac myosin, and S100 proteins (for 
review see [5]).
3.  TLR-mediated signaling pathways: network of adaptor molecules and 
transcription factors
Ligand recognition by TLRs involves the recruitment of different TIR domain-
containing adaptor proteins. The types of adaptor proteins they use at least in part 
explain distinct functions of TLRs.
To date, there have been four adaptor proteins found to interact with specific 
TLRs (Table 2). Myeloid differentiation primary response 88 (MyD88) was the first 
of its kind. It is an intracytoplasmic adaptor molecule that consists of a C-terminal 
TIR domain and an N-terminal death domain. Its TIR domain—which is funda-
mental to ligand site recognition—can interact with all TLRs with the exception of 
TLR3. Recruitment of MyD88 by TLRs initiates the cascades of mitogen-activated 
protein kinases (MAPKs) and nuclear factor-κB (NF-κB) that result in the produc-
tion of inflammatory cytokines.
In this context, TIR-domain-containing adapter-inducing interferon-β (TRIF) 
is another adaptor protein. TLR3 and also TLR4 can act as a trigger for TRIF-
dependent signaling. This signaling then utilizes transcription factors NF-κB and 
interferon regulatory factor 3 (IRF3) to produce inflammatory cytokines and type 
I IFN.
Toll-interleukin 1 receptor (TIR) domain-containing adaptor protein 
(TIRAP) and TRIF-related adaptor molecule (TRAM) are last two remaining 
TIR domain-containing adaptor proteins. They are specialized for directing 
other adaptors to specific TLRs and thus are referred to as sorting adaptors. 
TIRAP serves as the sorting adaptor for MyD88 and facilitates its recruitment to 
TLR1, TLR2, TLR4, and TLR6, while TRAM is merely involved in the interaction 
between TRIF and TLR4.
In this manner, the discussion on signaling pathways mediated by TLRs is com-
monly held in MyD88-dependent and TRIF-dependent settings (for review see [7]). 
Figure 1 is a schematic diagram of TLR location and pathways.
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3.1 TLRs and different disease entities
Studies in mice have demonstrated that TLR signaling change underlies a range 
of pathologies. Supporting this, human studies propose that single nucleotide 
polymorphisms (SNPs) that alter—whether upregulated or downregulated—TLR 
signaling may predispose to or protect from development of diseases [8].
Figure 1. 
Toll-like receptor (TLR) location and signaling pathways.
Signaling adaptor(s) Transcription 
factor(s)
Products
MyD88-
dependent 
signaling
TRIF-
dependent 
signaling
Sorting 
adaptor
Inflammatory 
cytokines
Type 
I IFN
TLR1  × TIRAP NF-κB  ×
TLR2  × TIRAP NF-κB  ×
TLR3 ×  × NF-κB, IRF3, 
and IRF7
 
TLR4   TIRAP 
and 
TRAM
NF-κB, IRF3, 
and IRF7
 
TLR5  × × NF-κB  ×
TLR6  × TIRAP NF-κB  ×
TLR7  × × NF-κB and IRF7  
TLR8  × × NF-κB and IRF7  
TLR9  × × NF-κB and IRF7  
Table 2. 
Toll-like receptor: signaling pathways and products [6].
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3.2 Autoimmunity
All 10 TLRs that are present in humans (except to TLR5) have been associated 
with autoimmune and inflammatory diseases including arthritis, systemic lupus 
erythematosus, scleroderma, and Sjogren’s syndrome [9]. There are potential 
opposing views on involvement of TLRs in autoimmunity.
Autoimmunity is referred to as conditions where the immune system is fighting 
against the body itself by production of antibodies, the so-called autoantibodies, 
against self molecules, the so-called autoantigens. Autoantibodies bind to autoanti-
gens and form immune complexes. The cytokine interferon-alpha (IFNα) was first 
thought to have a pure white role of antiviral immunity. However, the observations 
of autoimmune features caused by the use of recombinant IFNα in patients with 
chronic viral infections have expanded the former function of IFNα far beyond 
antiviral immunity to autoantibody production and autoimmunity. A hypoth-
esis is that immune complexes having nucleic acids can act as ligands for TLRs, 
thereby making the innate immune cells to induce more than wanted or unwanted 
responses. TLRs that can recognize nucleic acids, i.e., TLR7 and TLR9, and plas-
macytoid dendritic cells (pDCs) that express these receptors and produce IFNα in 
response are of particular importance in this context [9]. In contrast, some TLRs 
have been reported to turn the knob in the opposite direction. When reviewing the 
role of TLRs in inflammatory arthritis, TLRs may stimulate osteoclastogenesis, and 
on the other side, there are TLRs that inhibit activation of osteoclasts and thus can 
prevent bone destruction [10].
3.3 Brain diseases
Different brain cells reveal the expression of TLRs:
Microglia express all TLRs.
Neurons express TLR3, TLR7, TLR8, and TLR9.
Astrocytes express TLR2, TLR3, and TLR9.
Oligodendrocytes express TLR2 and TLR3.
The role of TLRs has been characterized in the normal central nervous system 
(CNS) as well as in disease states of the CNS. Experimental evidence suggests the pos-
sible role of TLR2 in neurogenesis, whereas TLR3 and TLR4 apparently act as downreg-
ulators of neurogenesis. Enhancement of hippocampal-dependent working memory in 
mice lacking TLR3 implicates this receptor as a negative regulator of cognitive functions 
as well. In bacterial infections of the brain and abscess formation, TLR2, TLR4, and 
TLR9 are essential to elicit immune responses. In the cases of viral meningitis, TLR3 
and TLR9 engagement can help to localize infection and diminish neural injury as well. 
In parasite infections of the brain, TLR1, TLR2, and TLR9 show paradoxical effects—
they may worsen disease rather than clear parasites from the brain. Both models of 
neuronal injury and of spinal cord injury indicate a role for TLR2 and TLR4 in inducing 
neuronal death and axon and myelin damage. Finally, evidence points to the potential 
role that TLR2, TLR4, TLR5, TLR7, and TLR9 can play in preventing the accumulation 
of amyloid plaques and progression of Alzheimer’s disease [11].
3.4 Cardiovascular diseases
Cardiac myocytes show the expression of TLR2, TLR3, TLR4, and TLR6. TLRs 
play paradoxical roles in different myocardial diseases. For example, TLR2 was 
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shown to mediate apoptosis of cardiac myocytes induced by hydrogen peroxide 
and doxorubicin, while TLR4 attenuated apoptosis of cardiac myocytes. Targeting 
both TLR2 and TLR4 provided protection in septic cardiomyopathy. TLR4 blockade 
implied benefit to ischemia-reperfusion injury and cardiac hypertrophy as well (for 
review see [12]).
TLR4 is also said to be highly expressed in atherosclerotic lesions which 
inflammation is supposed to corporate in its nature. There are possible explana-
tions which can be given to this fact. The oxidization of lipids as a way to form 
atherosclerotic lesions accompanies thermal stress through HSP production. 
Oxidized lipids and HSPs can act as ligands and upregulate MyD88-dependent 
TLR4 relevant to inflammatory cytokine production. Another explanation is 
that TLR4 mediates recognition of Chlamydia pneumoniae, which in turn is 
closely related to atherosclerosis. In this manner, it would be understandable 
that individuals carrying Asp299Gly and Thr399Ile—which interfere with TLR4 
function—develop less atherosclerotic vascular events, such as carotid stenosis, 
acute coronary events, acute myocardial infarction, diabetic neuropathy, and 
allograft rejection [13]. On the other hand, TLRs, in particular TLR2, TLR4, TLR7, 
and TLR9, by the aid of adenosine, can succeed in angiogenesis after myocardial 
injury [12].
3.5 Infections
As described above, TLR4 is critical in recognizing LPS of gram-negative 
bacteria (GNB). People’s reactions are different to LPS inhalation and range 
from tolerance, i.e., no reaction, to strong asthma-like reactions. SNPs of human 
TLR4 gene, i.e., Asp299Gly and Thr399Ile, have been reported to affect the 
degree of reaction to LPS among healthy subjects and allergic asthmatic patients, 
development of septic shock by GNB, incidence of severe respiratory syncytial 
virus (RSV) bronchiolitis, risk of GNB colonization and of premature birth in 
pregnant women, and incidence of infections by GNB in patients on an intensive 
care unit [13].
3.6 Kidney diseases
Less is understood about the role of TLRs in kidney diseases. However, experi-
mental evidence suggests that all TLRs are involved in sepsis and renal infections. 
Each TLR has its own associations with distinct renal diseases as well (for review 
see [14]).
3.7 Liver diseases
In the liver, TLR expression is observed on a variety of cells including Kupffer 
cells (TLR2, TLR3, TLR4, and TLR9), hepatocytes (all TLRs), hepatic stellate cells 
(TLR2, TLR4, and TLR9), biliary epithelial cells (TLR2, TLR3, TLR4, and TLR5), 
sinusoidal epithelial cells (TLR4), hepatic dendritic cells (TLR2, TLR4, TLR7, and 
TLR9), hepatic natural killer cells (TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, and 
TLR9), and hepatic B cells (TLR2, TLR4, TLR7, and TLR9). Undoubtedly, such 
widely distrusted TLRs have been an important part of multiple liver diseases 
including infections of the liver by L. monocytogenes, and S. typhimurium, P. 
falciparum, hepatitis C virus, and hepatitis B virus, alcohol-induced liver diseases, 
nonalcoholic fatty liver disease, hepatic fibrosis, liver injury, liver regeneration, 
and hepatocellular carcinoma, and hepatic immune disorders (for review see [15]).
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3.8 Malignancies
As for other sections, TLRs present positive and negative effects in tumorigen-
esis which have been discussed in [16].
3.9 Other diseases
The possible role of TLRs in periodontal health, lung diseases, and dermatologi-
cal diseases has been reviewed in detail elsewhere [17–19].
4. Clinical implications
4.1 TLR agonists
TLR agonists have offered to help boosting the immune responses to vaccination 
as well as potential for immunotherapy of cancer, allergy, and infections. Three of 
which have received approval by the Food and Drug Administration (FDA) and are 
listed here:
 Bacillus Calmette-Guérin (BCG) can act as an agonist of TLR2/TLR4 and be 
used for treatment of superficial transitional cell carcinoma of the bladder.
 Monophosphoryl lipid A (MPL) can cause activation of TLR2/TLR4 recom-
mended for the prophylaxis of human papilloma virus (HPV)-associated 
cervical cancer.
 Imiquimod functions as a TLR7 agonist with implications for the treatment of 
actinic keratosis, basal cell carcinoma, and genital and perianal warts [20].
4.2 TLR antagonists
Antagonists targeting TLR-mediated signaling have displayed anti-inflamma-
tory features that may be effective against invading pathogens and autoimmune 
diseases.
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